Business
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"More Than 25,000 People in Japan Are Eligible for Genetic Testing\nSALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has received reimbursement and launched the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) in Japan to help physicians determine which people affected with breast and ovarian cancer have Hereditary Breast and Ovarian Cancer (HBOC) syndrome and qualify for additional diagnostic and medical management. BRACAnalysis previously was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) in November 2019 for this indication.\n “We are excited that the BRACAnalysis Diagnostic System is now available to assess HBOC risk in people with breast and ovarian cancer,” said Seigo Nakamura, M.D., Ph.D., Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University Hospital in Tokyo and president of the Japanese Organization of Hereditary Breast and Ovarian Cancer (JOHBOC). “Our goal is to use the BRACAnalysis test to identify patients with BRCA mutations who may need more advanced diagnostic and medical care.” Effective immediately, physicians can order the BRACAnalysis test for affected patients who meet the genetic testing criteria defined by JOHBOC including: Presence of BRCA1 or BRCA2 pathogenic mutations in family members.Individual has breast cancer and meets any of the following: Breast cancer under 45,Triple-negative breast cancer aged 60 or younger,Two or more primary breast cancers,One or more third-degree relatives with breast or ovarian cancer. Individual has ovarian, fallopian tube, and peritoneal cancers.Male breast cancer.Tumor tissue profiling tests that suggest retention of BRCA1 or BRCA2 germline pathogenic mutation if cancer eligibility criteria for companion diagnosis for PARP inhibitor are met. Myriad estimates that more than 25,000 people in Japan currently meet the testing criteria, and the company has partnered with SRL Inc., a subsidiary of Miraca Group, to commercialize the BRACAnalysis Diagnostic System in Japan. “BRACAnalysis is the gold standard for germline BRCA1 and BRCA2 testing worldwide,” said Raymond Francot, executive vice president of International Operations, Myriad Genetics. “We are excited ...